MedPath

Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

Phase 3
Withdrawn
Conditions
Cognitive Late Effects
Cancer
Registration Number
NCT00255138
Lead Sponsor
Temple University
Brief Summary

The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.

Detailed Description

In previous years, it had often been assumed that cognitive and behavioral declines in children who survived cancer therapy were largely a function of the prophylactic therapies (e.g., radiation, chemotherapy) that these children had received. Regardless of the etiologies of these specific late effects, the data regarding the long-term outcome of these children are strikingly consistent. Generally, the studies to date suggest significant impairments in attention and concentration that result in marked declines in academic performance and social and behavior difficulties.

Despite the clear evidence of problems with attention and concentration, as well as associated fucntional impairments (e.g., poor academic achievement and poor peer relationships), there have been few clinical trials designed to manage the cogntive late effects and neurological toxicities associated with radiation therapy and chemotherapy for children and adolescents who have survived cancer.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Age 6-18
  • Patient has received chemotherapy, radiation, or a combination of both.
  • Patient is at least 12 months post-competion of therapy but no more than five years post-completion of therapy.
Exclusion Criteria
  • No ongoing pharmacological management of ADHD
  • Not currently pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Conner's Parent Rating Scale (CPRS)
Secondary Outcome Measures
NameTimeMethod
Continuous Performance Test (CPT)
Side Effects Rating Scale
Conner's Teacher Rating Scale (CTRS)

Trial Locations

Locations (1)

Temple University

🇺🇸

Philadelphia, Pennsylvania, United States

Temple University
🇺🇸Philadelphia, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.